<?xml version="1.0" encoding="UTF-8"?>
<ref id="B13-biomedicines-08-00060">
 <label>13.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Long</surname>
    <given-names>G.V.</given-names>
   </name>
   <name>
    <surname>Stroyakovskiy</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Gogas</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Levchenko</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>De Braud</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Larkin</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Garbe</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Jouary</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Hauschild</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Grob</surname>
    <given-names>J.-J.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial</article-title>
  <source>Lancet</source>
  <year>2015</year>
  <volume>386</volume>
  <fpage>444</fpage>
  <lpage>451</lpage>
  <pub-id pub-id-type="doi">10.1016/S0140-6736(15)60898-4</pub-id>
  <pub-id pub-id-type="pmid">26037941</pub-id>
 </element-citation>
</ref>
